Disha Rao
Netherlands Cancer Institute
7 Papers
Disha Rao is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink,Sangeetha M. Reddy,Jianjun Gao,Shaojun Zhang,Rafet Basar,Rohit Thakur,Keren Yizhak,Moshe Sade-Feldman,Moshe Sade-Feldman,Jorge Blando,Guangchun Han,Vancheswaran Gopalakrishnan,Yuanxin Xi,Hao Zhao,Rodabe N. Amaria,Hussein Abdul-Hassan Tawbi,Alex P. Cogdill,Wenbin Liu,Valerie S. LeBleu,Fernanda G. Kugeratski,Sapna Pradyuman Patel,Michael A. Davies,Patrick Hwu,Jeffrey E. Lee,Jeffrey E. Gershenwald,Anthony Lucci,Reetakshi Arora,Scott E. Woodman,Emily Z. Keung,Pierre Olivier Gaudreau,Alexandre Reuben,Christine N. Spencer,Elizabeth M. Burton,Lauren E. Haydu,Alexander J. Lazar,Roberta Zapassodi,Courtney W. Hudgens,Deborah A. Ledesma,SuFey Ong,Michael Bailey,Sarah Warren,Disha Rao,Oscar Krijgsman,Elisa A. Rozeman,Daniel S. Peeper,Christian U. Blank,Ton N. Schumacher,Lisa H. Butterfield,Monika A. Zelazowska,Kevin M. McBride,Raghu Kalluri,James P. Allison,Florent Petitprez,Florent Petitprez,Wolf H. Fridman,Wolf H. Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Nir Hacohen,Nir Hacohen,Katayoun Rezvani,Padmanee Sharma,Michael T. Tetzlaff,Linghua Wang,Jennifer A. Wargo +64 more
TL;DR: B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders and insights are provided into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Irene L.M. Reijers,Disha Rao,Judith M. Versluis,Alexander M. Menzies,Petros Dimitriadis,Michel W.J.M. Wouters,Andrew J. Spillane,W. Martin C. Klop,Annegien Broeks,Linda J.W. Bosch,Marta Lopez-Yurda,W. van Houdt,Robert V. Rawson,Lindsay G Grijpink-Ongering,María Jesús González González,Sten Cornelissen,Jasper Bouwman,Joyce Sanders,Elsemieke I. Plasmeijer,Y.S. Elshot,Richard A. Scolyer,B. A. Van De Wiel,Daniel S. Peeper,Alexander C.J. van Akkooi,Georgina V. Long,Christian U. Blank +25 more
TL;DR: In this article , a baseline IFN-γ signature enables prospective selection of patients who can benefit from anti-PD-1 monotherapy in the DONIMI trial, where domatinostat (a class I HDAC inhibitor) does not add benefit to neoadjuvant anti- PD-1 ± anti-CTLA-4 in patients.
34
Acidity‐mediated induction of FoxP3+ regulatory T cells
Disha Rao,Johanna A Stunnenberg,Ruben Lacroix,Petros Dimitriadis,Joanna Kaplon,F A Verburg,Paula T van Royen,Esmée P. Hoefsmit,Kathrin Renner,Christian U. Blank,Daniel S. Peeper +10 more
TL;DR: In this article , the authors observed increased TGFβ-mediated induction of Forkhead box P3+ (FoxP3+) cells in the presence of extracellular lactic acid, in a glycolysisindependent, acidity-dependent manner.
9
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Elisa A. Rozeman,Judith M. Versluis,Karolina Sikorska,Esmée P. Hoefsmit,Petros Dimitriadis,Disha Rao,Ruben Lacroix,Lindsay G Grijpink-Ongering,Marta Lopez-Yurda,Birthe Heeres,B. A. Van De Wiel,Claudie C. Flohil,A. Sari,Stijn W.T.P.J. Heijmink,D. Van Den Broek,Annegien Broeks,Jan Willem B. de Groot,Marieke A. Vollebergh,Sofie Wilgenhof,Johannes V. van Thienen,John B. A. G. Haanen,Christian U. Blank +21 more
TL;DR: Implementing short-term addition of intermittent D+T to PEM seems a more feasible, tolerable and an effective alternative for the continuous triple combination and gives the opportunity to treat with second line targeted therapy after disease progression.
6
MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance
Disha Rao,Ruben Lacroix,Tainá Martins Gomes,Johanna A Stunnenberg,Mesele C Valenti,Petros Dimitriadis,Chun-Pu Lin,Beaunelle de Bruijn,Oscar Krijgsman,Maarten A. Ligtenberg,Daniel S. Peeper,Christian U. Blank +11 more
TL;DR: MeVa2.1.2.dOVA as discussed by the authors is derived from the same primary tumor induced on BrafV600E Pten−/− mice, and it was transiently controlled in vivo by either targeted therapy, adoptive T cell transfer, regulatory T cell depletion, or immune checkpoint blockade.
3